TY - JOUR
T1 - Covalent Targeting As a Common Mechanism for Inhibiting NLRP3 Inflammasome Assembly
AU - Stanton, Caroline
AU - Sun, Jie
AU - Nutsch, Kayla
AU - Rosarda, Jessica D.
AU - Nguyen, Thu
AU - Li-Ma, Chloris
AU - Njomen, Evert
AU - Melillo, Bruno
AU - Kutseikin, Sergei
AU - Saez, Enrique
AU - Cravatt, Benjamin F.
AU - Teijaro, John R.
AU - Wiseman, R. Luke
AU - Bollong, Michael J.
N1 - Publisher Copyright:
© 2024 American Chemical Society.
PY - 2024/2/16
Y1 - 2024/2/16
N2 - The NLRP3 inflammasome is a cytosolic protein complex important for the regulation and secretion of inflammatory cytokines, including IL-1β and IL-18. Aberrant overactivation of NLRP3 is implicated in numerous inflammatory disorders. However, the activation and regulation of NLRP3 inflammasome signaling remain poorly understood, limiting our ability to develop pharmacologic approaches to target this important inflammatory complex. Here, we developed and implemented a high-throughput screen to identify compounds that inhibit the inflammasome assembly and activity. From this screen, we identify and profile inflammasome inhibition of 20 new covalent compounds across nine different chemical scaffolds, as well as many known inflammasome covalent inhibitors. Intriguingly, our results indicate that NLRP3 possesses numerous reactive cysteines on multiple domains whose covalent targeting blocks the activation of this inflammatory complex. Specifically, focusing on compound VLX1570, which possesses multiple electrophilic moieties, we demonstrate that this compound allows covalent, intermolecular cross-linking of NLRP3 cysteines to inhibit inflammasome assembly. Our results, along with the recent identification of numerous covalent molecules that inhibit NLRP3 inflammasome activation, further support the continued development of electrophilic compounds that target reactive cysteine residues on NLRP3 to regulate its activation and activity.
AB - The NLRP3 inflammasome is a cytosolic protein complex important for the regulation and secretion of inflammatory cytokines, including IL-1β and IL-18. Aberrant overactivation of NLRP3 is implicated in numerous inflammatory disorders. However, the activation and regulation of NLRP3 inflammasome signaling remain poorly understood, limiting our ability to develop pharmacologic approaches to target this important inflammatory complex. Here, we developed and implemented a high-throughput screen to identify compounds that inhibit the inflammasome assembly and activity. From this screen, we identify and profile inflammasome inhibition of 20 new covalent compounds across nine different chemical scaffolds, as well as many known inflammasome covalent inhibitors. Intriguingly, our results indicate that NLRP3 possesses numerous reactive cysteines on multiple domains whose covalent targeting blocks the activation of this inflammatory complex. Specifically, focusing on compound VLX1570, which possesses multiple electrophilic moieties, we demonstrate that this compound allows covalent, intermolecular cross-linking of NLRP3 cysteines to inhibit inflammasome assembly. Our results, along with the recent identification of numerous covalent molecules that inhibit NLRP3 inflammasome activation, further support the continued development of electrophilic compounds that target reactive cysteine residues on NLRP3 to regulate its activation and activity.
UR - http://www.scopus.com/inward/record.url?scp=85182554769&partnerID=8YFLogxK
U2 - 10.1021/acschembio.3c00330
DO - 10.1021/acschembio.3c00330
M3 - Article
C2 - 38198472
AN - SCOPUS:85182554769
SN - 1554-8929
VL - 19
SP - 254
EP - 265
JO - ACS chemical biology
JF - ACS chemical biology
IS - 2
ER -